Cytomegalovirus Treatment Market to Grow at 3% in 2019: FMI Study - Reuters

 

Cytomegalovirus Treatment Market to Grow at 3% in 2019: FMI Study

Cytomegalovirus Treatment Market to Grow at 3% in 2019: FMI Study

Tue Feb 12, 2019 - 03:30am UTC

Future Market Insights has announced the addition of the “Cytomegalovirus Treatment Market: Improvement in Efficacy of Combinational Antiviral Therapy and Growing Awareness Regarding Cytomegalovirus Infections Expected to Enhance Revenue Growth: Global Industry Analysis 2013 – 2017 and Opportunity Assessment 2018 – 2028″ report to their offering.

Valley Cottage, United States – February 11, 2019

The cytomegalovirus treatment market is poised to grow at an impressive y-o-y of over 5.5% in 2019, as per the latest research study published by FMI. A cohort of macro factors, including rapid adoption of innovative treatment procedures and burgeoning investments in healthcare, are auguring well for the wide-spread adoption of cytomegalovirus treatment. These insights are per the latest FMI research study that conveys a healthy outlook for global cytomegalovirus market in 2019 and beyond.

Patient pool affected by cytomegalovirus is on a consistent rise, necessitating adoption of effective treatment methods and therapies. As per a revelation by the MedlinePlus, between 50 percent and 80 percent of adults in the US have suffered from cytomegalovirus by the age of 40. Statistics as such demonstrate augmented adoption of cytomegalovirus treatment products and procedures in the future, creating sustained opportunities for the manufacturers to reap sizeable revenues.

As per the FMI report, demand for valganciclovir drug continues to be buoyant on account of effective results if taken at evenly spaced intervals, with global sales likely to surpass US$ 55.5 Mn in 2019. In addition to this, valganciclovir is less time-consuming and affordable, which is further adding to its popularity in the cytomegalovirus treatment space.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8665

“The drug development framework for treatment of cytomegalovirus continues to be progressive, offering ample scope for development of new products and procedures. There are multiple clinical trials being performed for cytomegalovirus treatment worldwide, led by prominent regions including Europe and North America. The late-stage pipeline comprises exceptional drugs which are envisioned to enter the market. This, in turn, is likely to create favorable scenario for cytomegalovirus treatment market over the forecast period”, says FMI report.

Hospital Pharmacies Remain Highly Lucrative Channel for Manufacturers with Notable ROI Benefits

As per the report, congenital CMV infection registers substantial demand for cytomegalovirus treatment, with global sales expected to surpass over US$ 65.5 Mn in 2019. Hospital pharmacies are likely to steer sales of cytomegalovirus treatment products and procedures, owing to reliable offerings at reasonable costs. The well-informed and modern patients seek a combination of efficiency with convenience, which is making e-commerce a rapidly growing distribution channel for manufacturers to commercialize their offerings.

As per the report, high cost of cytomegalovirus treatment procedures remains a key factor hampering adoption and deterring market’s growth potential. Along with high prices, associated side effects of cytomegalovirus treatment products and procedures are denting end-user confidence. Some of the prevalent side effects associated with cytomegalovirus treatment products and procedures include neutropenia, nausea, thrombocytopenia, hematological toxicity, renal dysfunction, and so on.

Request Methodology of this Report @ https://www.futuremarketinsights.com/askus/rep-gb-8665

Manufacturers in the cytomegalovirus treatment market are focusing on novel developments, resulting in upgraded products with ameliorated functionalities. The market players are also focusing on product availability in varying size dimensions for increased convenience of end-users. The cytomegalovirus treatment market is witnessing a series of strategic partnerships, acquisitions, and mergers, which enables the manufacturing companies to offer viable offerings by combining their production expertise. For instance, Johnson & Johnson completed the acquisition of Ci:z Holdings Co., Ltd. in 2019 for expanding its exclusive portfolio of science-based dermocosmetic beauty products.

Request to Browse Report Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-8665

More from Healthcare, Pharmaceuticals and Medical devices Market:

Bronchoscopes Market Revenue Opportunity Analysis 2019

Endoscopy Fluid Management Systems Sales Report 2019

Endoscopy Visualization Systems Strategic Outlook

Contact Info:
Name: Abhishek Budholiya
Organization: Future Market Insights
Address: 616 Corporate Way,, Suite 2-9018,, Valley Cottage,
Phone: 3479183531
Website: https://www.futuremarketinsights.com/reports/cytomegalovirus-treatment-market

This content is not produced by Reuters Editorial News. It is produced by VC NewsNetwork. For content enquiry, please reach us at

Latest News >

Combining fashion with the trillion dollar "love economy", the wedding giant Jiahao International Holdings will reshape the global marriage industry.

Future Market Insights has announced the addition of the “Cytomegalovirus Treatment Market: Improvement in Efficacy of Combinational Antiviral Therapy and Growing Awareness Regarding Cytomegalovirus Infections Expected to Enhance Revenue Growth: Global Industry Analysis 2013 – 2017 and Opportunity Assessment 2018 – 2028″ report to their offering. Valley Cottage, United States – February 11, 2019 — […]

08:29am UTC

Koku nets US$2 million in Pre-Series A funding from Tencent’s Jason Zeng

For its next Series A funding, Koku said it is confident to raise a target of US$10 million.

03:34am UTC

Indonesian Fishery Platform Aruna Announced Winner Of Alipay-NUS Enterprise Social Innovation Challenge

The joint initiative by Ant Financial and National University of Singapore is a step towards building an inclusive society by harnessing the power of technology.

07:23am UTC

RHL Ventures set ups US$24 million fund for Malaysian startups, SMEs

This fund represents one of the first public and private collaborations between RHL Ventures and SME Corp Malaysia.

07:07am UTC

SBIF, COPE Private Equity invest US$14.25 million in Malaysia’s MDT Innovations

The funding capital will be used to support the startup’s research and development and enhance its product quality.

06:15am UTC